Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Other Non Operating Income (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Other Non Operating Income for 5 consecutive years, with $57000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income rose 129.23% to $57000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 87.76% year-over-year, with the annual reading at $1.3 million for FY2025, 43.55% down from the prior year.
  • Other Non Operating Income for Q4 2025 was $57000.0 at Rhythm Pharmaceuticals, down from $274000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $100.0 million in Q1 2021, with the low at -$644000.0 in Q1 2025.
  • Average Other Non Operating Income over 5 years is $6.5 million, with a median of -$17000.0 recorded in 2023.
  • The sharpest move saw Other Non Operating Income skyrocketed 52452.94% in 2024, then tumbled 222.9% in 2025.
  • Over 5 years, Other Non Operating Income stood at $100.0 million in 2021, then plummeted by 100.42% to -$420000.0 in 2022, then soared by 187.86% to $369000.0 in 2023, then crashed by 152.85% to -$195000.0 in 2024, then skyrocketed by 129.23% to $57000.0 in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at $57000.0, $274000.0, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.